UBC PiMS Research Group
Pharmacoepidemiology in Multiple Sclerosis Research Group

Professor Helen Tremlett

Professor Helen Tremlett, PhD

Currently a professor at the University of British Columbia, Vancouver in the Faculty of Medicine, Division of Neurology and the Canada Research Chair in Neuroepidemiology and Multiple Sclerosis. Also funded by the MS Society of Canada’s Don Paty Career Development Award and a Michael Smith Foundation for Health Research Scholar award. Also holds operating grants from CIHR, the US National MS Society and the UK MS Trust. Trained in pharmacoepidemiology/ multiple sclerosis with a PhD from Cardiff University, UK. Heads the ‘Pharmacoepidemiology in MS (PiMS) Research group.’ Current research interests include: the natural history of MS; prognosis and predictors of disease progression in MS; effectiveness of the immunomodulatory drugs (IMDs) in MS; adverse effects of the MS IMDs; MS epidemiology; cancer and MS; pregnancy outcomes and MS; vitamin D, sunlight, infections and MS disease activity.

Published Refereed Papers | In Press | Invited Editorials | Book Chapters | Research Letters and Case Reports

____________________________________________________________________________________________________________________

Published Refereed Papers

1. Tremlett H, Luscombe DK, Wiles CM: Use of Corticosteroids in Multiple Sclerosis byUK Consultant Neurologists. Journal of Neurology, Neurosurgery and Psychiatry 1998;65:362-365.

2. Tremlett H, Luscombe DK: Multiple Sclerosis. Pharmaceutical Journal 1998;260:29-38.

3. Tremlett H, Wiles CM: Oral or intravenous?  The evidence for corticosteroids in Multiple Sclerosis.  Progress in Neurology and Psychiatry 1999;3(1):19-23

4. Tremlett H, Luscombe DK: Beta-interferon in the treatment of Multiple Sclerosis. Journal of Applied Therapeutic Research 1999;2(4):235-242.

5. Tremlett H, Wiles CM, Luscombe DK Non-prescription medicine use in an MS clinic population; British Journal of Clinical Pharmacology 2000;50(1):55-60.

6. Tremlett H, Wiles CM, Luscombe DK Prescribing for Multiple Sclerosis patients in General Practice: a case-control study Journal of Clinical Pharmacy and Therapeutics; 2001;26(6):437-444.

7. Tremlett H, J Evans, C Rogers, CM Wiles, DK Luscombe Asthma and Multiple Sclerosis: an inverse association in a case-control general practice population; Quarterly Journal of Medicine; 2002;95:753-756.

8. Tremlett H, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS Neurology 2003;61:551-554.

9. Tremlett H, Oger J Adherence from across the pond: six-years of experience with the beta-interferons prescribed for Multiple Sclerosis, Pharmaceutical Journal 2003; 271:649-653.

10. Tremlett H, Yoshida E, Oger J. Liver injury associated with the IFNBs for MS: a comparison between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im). Neurology 2004;62:628-631.

This publication was selected by Neurology to have an accompanying Patient Page:
Aguilar, M. MS treatment: Some safety issues to keep in mind. Neurology 2004;62:8-9. As stated by the journal, the Neurology Patient Page provides ‘a critical review of ground-breaking discoveries in neurological research that are written especially for patients and their families.’

11. Tremlett H, Oger J. Elevated aminotransferases during treatment with Beta-Interferon for Multiple Sclerosis: actions and outcomes. Multiple Sclerosis 2004;10:298-301

12. Tremlett H, Porciuncula J, Gibbs E, Oger J Binding antibodies and aminotransferases in beta-interferon beta treated patients with multiple sclerosis. Journal of Applied Therapeutic Research 2004;5(1):12-16

13. Tremlett H, Oger J Hepatic injury, liver monitoring and the beta-interferons for Multiple Sclerosis (Review) Journal of Neurology 2004;251:1297-1303

14. Tremlett H, Porciuncula J, Oger J Treatment with beta-interferon prior to glatiramer acetate diminishes the serum IgG response in multiple sclerosis patients. Journal of Applied Therapeutic Research 2004;5(2):12-16.

15. Tremlett H, Paty D, Devonshire V The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65:1919-1923.

16. Tremlett H, Paty D, Devonshire V. Disability progression in MS is slower than previously reported. Neurology. 2006;66:172-177.

This publication was highlighted by Neurology. This is the most frequently read section of the Journal; a limited number of papers are highlighted each issue:

Disability progression in multiple sclerosis (MS) Neurology. 2006;66:157

And had an accompanying Commentary:

Pittock, S. Therapeutic decision making in MS: Impact of a slower disability progression. Neurology. 2006;66:157.

17.  Tremlett H,Devonshire V. Does the season or month of birth influence disease progression in multiple sclerosis? Neuroepidemiology 2006;26:195-198

18. Tremlett H,Devonshire V. Is late onset multiple sclerosis associated with a worse outcome? Neurology 2006;67:954-959

19. Tremlett H, Seemüller S, Zhao Y, Yoshida EM, Oger J. Petkau J. Liver test abnormalities in multiple sclerosis: findings from placebo treated patients. Neurology 2006;67:1291-1293

20. Sayao AL, Devonshire V, Tremlett H. Longitudinal Follow-up of Benign MS at 20 years. Neurology. 2007 Feb 13;68(7):496-500.

Contribution: Methodological advice, carried out all statistical analyses, presentation of data graphically and in table form. Guided drafting of manuscript, critical review of final manuscript (20% effort). Corresponding author.

This publication was highlighted by Neurology:

Benign MS at 20 years Neurology. 2007;68:478

And had an accompanying Commentary:

Pittock, S. Does benign multiple sclerosis today imply benign multiple sclerosis tomorrow?

Implications for treatment. Neurology. 2007;68:480-481.

21. Tremlett H, Oger J. Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective. Multiple Sclerosis 2008; 14:94-105

22. Tremlett H, Zhao Y, Devonshire V. The natural history of secondary-progressive multiple sclerosis Multiple Sclerosis 2008. 14: 314–324

This paper was accompanied by an Editorial: Confavreux, C. Defining the natural history of MS: the need for complete data and rigorous definitions Multiple Sclerosis 2008; 14(3): 289 – 291.

23. Forwell S, Brunham S, Tremlett H, Morrison W, Tentzerakis S, Bogle N, Oger J. Primary and non-primary fatigue in multiple sclerosis. International Journal of MS Care. 2008;10:14-20

Contribution: Assessing the effects of medication on fatigue.  I contributed to the study design (collection of drug data) and provided drug information for individual patient cases. I also helped with the statistical analysis and critical review of the final manuscript. 5% effort.

24. Koch M, De Keyser J, Tremlett H Timing of birth and disease progression in multiple sclerosis. Multiple Sclerosis 2008; 14:793-798.

Contribution: 50%

 

25. Tremlett H, Van der Mei I, Pittas F, Blizzard L, Paley G, Dwyer T, Taylor B, Ponsonby AL. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiology and Drug Safety 2008 17(6):565-76.

26. Tremlett H, Zhao Y, Joseph J,Devonshire V and the UBC MS Clinic Neurologists. Relapses in multiple sclerosis are age and time-dependent. J Neurol Neurosurg Psychiatry 2008;79;1368-1374

27. Tremlett H, van der Mei I, Pittas F, Blizzard L, Paley G, Mesaros G, Woodbaker R, Nunez M, Dwyer T, Taylor B, Ponsonby AL. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology. 2008; 31: 271-279

Accompanying Commentary:

Kesselring, J. Sunshine on MS. Neuroepidemiology. 2008; 31: 280-281

28. Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. Journal of Neurology. 2009 Mar;256(3):374-81

29. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y and the UBC Neurologists. The impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009; 73:1616-1623

Accompanying Editorial:

Editorial: Ruth Ann Marrie and Gary Cutter Relapses in multiple sclerosis. Important or not? Neurology 2009; 73:1612-1613

The paper was selected to appear on-line, ahead of print as a rapid communication with the ‘hare’ logo (only 1-5 papers are selected from each edition of the journal to appear in this form). In addition, the work was selected by Neurology, for the American Academy of Neurology’s press release program.

30. Koch M, Kingwell E, Rieckmann P and Tremlett H and the UBC Neurologists. The natural history of primary progressive MS. Neurology 2009; 73 1996-2002  

Contribution of my group: 100%.

31. Kingwell E, Leung A, Roger E, Duquette P, Rieckmann P, Tremlett Hand the UBC MS Neurologists. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. Journal of the Neurological Sciences 2010; 292:57-62

Contribution of my group: 80%.

32. Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, Tremlett H, and the UBC MS Clinic Neurologists. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010; 74 1822-1826

Contribution of my group: 90%.

33. Koch M, Zhao Y, Yee I, Guimond C, Kingwell E, Rieckmann P, Sadovnick S, Tremlett H. Age at disease onset in familial and sporadic primary progressive multiple sclerosis. Multiple Sclerosis. 2010. 2010;16 694-700

Contribution of my group: 80%.

34. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis (Review). Neurology 2010;74:2004-2015

35. Simpson S,  Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, Dwyer T, Gies P & Van der Mei I  Higher levels of serum 25-hydroxyvitamin D3 are associated with a reduced risk of relapse in multiple sclerosis. Annals of Neurology 2010;68:193-203

Contribution: 5%.

36. Koch M, Kingwell E, Rieckmann P, Tremlett H, and the UBC MS Clinic Neurologists. The natural history of secondary progressive MS. Journal of Neurology, Neurosurgery and Psychiatry. 2010;81(9):1039-43.

Contribution of my group: 100%.

Accompanying Editorial:

Chataway J. Progression is likely to occur earlier in young men with motor onset symptoms. Journal of Neurology, Neurosurgery and Psychiatry 2010;81:944-5

37. Shirani A, Tremlett H. The effect of smoking on the symptoms and progression of multiple sclerosis: a review. J Inflamm Res, 2010,3:115-26

Contribution of my group: 100%.

38. Chan S, Kingwell E, Oger J, Yoshida E, Tremlett H. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study. Multiple Sclerosis Journal 2011;17 361-367

Contribution of my group: 100%.

39. van der Kop ML, Pearce MS, Dahlgren L, Synnes A, Sadovnick AD, Sayao A, Tremlett H Neonatal and delivery outcomes in women with multiple sclerosis. Annals of Neurology. 2011 Jul;70(1):41-50

Contribution of my group: 100%.

40. Sayao AL, Bueno AM, Devonshire V, and the UBC MS Clinic Neurologists Tremlett H The psychosocial and cognitive impact of longstanding ‘benign’ multiple sclerosis Multiple Sclerosis Journal 2011 Nov;17(11):1375-83

Contribution of my group: 100%.

41. Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J and Tremlett H.  Relative mortality and survival in multiple sclerosis: Findings from British Columbia, Canada. Journal of Neurology, Neurosurgery & Psychiatry 2012 Jan;83(1):61-6. Epub 2011 Aug 23

Contribution of my group: 100%.

42. Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H Temporal trends of disability progression in multiple sclerosis Multiple Sclerosis Journal 2011 Sep 30. [Epub ahead of print]

Contribution of my group: 100%.

43. Lu E, Dahlgren L, Sadovnick AD, Sayao A, Synnes A, Tremlett H Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Multiple Sclerosis Journal 2011 Sep 13. [Epub ahead of print]

Contribution of my group: 100%.

44. Saeedi J, Rieckmann P, Yee I, Tremlett H and the UBC MS clinic neurologists. Characteristics of multiple sclerosis in aboriginals living in British Columbia (BC) Canada. Multiple Sclerosis Journal 2012 Mar 1. [Epub ahead of print]

Contribution of my group: 90%.

45. Evans C, Tam J, Kingwell E, Oger J, the BC MS Neurologists, Tremlett H. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clinical Therapeutics. 2012 Feb;34(2):341-50

Contribution of my group: 100%.

46. Marrie RA, Yu N, Leung S, Elliott L, Caetano P, Warren S, Wolfson C, Patten S, Svenson L, Tremlett H, Fisk J, Blanchard J, for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Rising prevalence of vascular comorbidities in MS: validation of administrative definitions for diabetes, hypertension, hyperlipidemia. Multiple Sclerosis Journal. 2012;18(9):1310-1319.

Contribution of my group: 5% [I helped gain funding for the overall study; drafted the original study design and edited the manuscript].

47. Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, Tremlett H. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain. 2012; 135:2973-2979

Selected by UBC-VCH for a media release: Multiple sclerosis patients have a lower risk of cancer. Covered by several media outlets, examples include: medical news today (http://www.medicalnewstoday.com/articles/247220.php); guardian.co.tt (http://www.guardian.co.tt/lifestyle/2012-07-01/cancer-risk-lower-multiple-sclerosis-patients); sciencedaily.com (http://www.sciencedaily.com/releases/2012/06/120621113329.htm)

48. Tremlett H, Zhu F, Petkau, J, Oger J, Zhao Y, and the UBC MS Clinic Neurologists. Natural, innate improvements in multiple sclerosis disability. Multiple Sclerosis Journal. 2012; 18(10):1412-1421.

Contribution of my group: 90%.

Accompanying Editorial:

Ontaneda D, Cohen JA. EDSS improvement: recovery of function or noise? Multiple Sclerosis Journal. 2012 Nov;18(11):1520-1.

Media coverage: Press release by UBC-VCH; The Globe and Mail ‘MS progression is not just a one-way street’: http://m.theglobeandmail.com/life/health-and-fitness/health/ms-progression-is-not-just-a-one-way-street/article4820438/?service=mobile

49. Lu E, Dahlgren L, Sadovnick AD, Synnes A, Tremlett H. Disease−Modifying Drugs for Multiple Sclerosis in Pregnancy: A Systematic Review. Neurology. 2012; 79(11):1130-1135

50. Shirani, A, Zhao Y, Karim M, Evans C, Kingwell E, van der Kop M, Oger J, Gustafson P, Petkau J, Tremlett H. Association between use of beta-interferon and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012 Jul 18;308(3):247-56.

The study examines a crucial question relevant to the treatment of MS – whether a commonly used, expensive group of drugs for multiple sclerosis (MS) – the beta-interferons – impact long-term disease progression in MS. Selected by JAMA for a media release (only 46 papers are selected for this each year) which included a video/interview posted on JAMA’s website (http://jama.jamanetwork.com/multimediaPlayer.aspx?mediaid=3727627). Selected for an accompanying Editorial from two world-renowned leaders and neurologists in the field of MS: Derfuss T, Kappos L. Evaluating the potential benefit of interferon treatment in multiple sclerosis. JAMA. 2012 Jul 18;308(3):290-1.
Stimulated extensive and lively debate in the wider community. Examples included:
Extensive media attention: Within one week of publication, there were 4 T.V. interviews (live on CTV National, taped on multiple evening news networks), and extensive news coverage, including the New York Times (http://www.nytimes.com/2012/07/18/health/research/multiple-sclerosis-drug-doesnt-stop-disability-study-finds.html), Globe and Mail, Vancouver Sun (‘Multiple sclerosis drug may not slow disease’s progression: UBC study’ http://www.vancouversun.com/health/Multiple+sclerosis+drug+slow+disease+progression+study/6947842/story.html) and Neurology Today (an official publication of the American Academy of Neurology; (http://www.aan.com/elibrary/neurologytoday/?event=home.showArticle&id=ovid.com:/bib/ovftdb/00132985-201209060-00004). Interviews with multiple outlets, including the Vancouver Sun, Healthday, WebMD, MSology (posted online: http://msology.ca/interview-with-researcher-helen-tremlett)
Commentaries in other journals: Greenberg BM, Balcer L, Calabresi PA, Cree B, Cross A, Frohman T, Gold R, Havrdova E, Hemmer B, Kieseier BC, Lisak R, Miller A, Racke MK, Steinman L, Stuve O, Wiendl H, Frohman E.Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2012 Nov 5:1-4.
Hohlfeld R. [Does interferon beta slow the progression of multiple sclerosis? Long-term effect of IFN-β on progression of physical disability is still not proven]. [Article in German]. tsch Med Wochenschr. 2012 Oct;137(41):2088.
Independent Podcasts: Do interferons help in the long run? Comments on the JAMA paper (Aug/2012) An interview with Dr. Douglas Goodin, medical director at the UCSF MS Center, covers a recent publication that calls interferon therapy into question
http://cit.ucsf.edu/podcast/description.php?uuid=98f4a6eb-dee9-44c5-9f62-45f5be5fd611
International recognition: Our JAMA paper’s contribution was officially recognized in the ‘2013 International Year of Statistics – Recognizing the Contributions of Statistics to Society worldwide’ (http://www.statistics2013.org/files/2012/12/STAT2013Poster.pdf)
The findings have also spawned multiple on-line discussion groups and really stimulated a much needed debate in the MS community

 

51. Marrie RA, Yu N, Leung S, Elliott L, Caetano P, Warren S, Wolfson C, Patten S, Svenson L, Tremlett H, Fisk J, Blanchard J, for the CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology. 2012 Oct 23;40(2):85-92.

Contribution of my group: 5%.

52. Marrie RA, Yu N, Leung S, Elliott L, Warren S, Wolfson C, Tremlett H, Blanchard J, Fisk J, for the CIHR Team in the Epidemiology and Impact of Comorbidity in Multiple Sclerosis. The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study. Multiple Sclerosis and Related Disorders Vol. 1, Issue 4, Pages 162-167

Contribution of my group: 5%.

53. Schuurman N, Amram O, Saeedi J, Rieckmann P, Yee I, and Tremlett H. A proposed methodology to estimate the cumulative life-time UVB exposure using Geographic Information Systems: an application to multiple sclerosis. Multiple Sclerosis and Related Disorders. 2013; 2: 29-35

Contribution of my group: 50%.
One of the figures was used on the cover page of the journal

54. Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber W.E., the UBC MS clinic neurologists and Tremlett H. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression Multiple Sclerosis Journal. 2013 Apr;19(5):577-84.

Contribution of my group: 90%.

55. Evans C, Kingwell E, Zhu F, Oger J, Zhao Y, Tremlett, H. Hospital admissions and multiple sclerosis: a retrospective, observational study examining temporal trends and patient characteristics in a Canadian cohort. Am J Manag Care 2012 Nov;18(11):735-42.

Contribution of my group: 100%.

56. Lu E, Zhao Y, Zhu F, van der Kop ML, Synnes A, Dahlgren L, Sadovnick AD, Sayao AL, Tremlett H. On behalf of the British Columbia Multiple Sclerosis Clinic Neurologists. Birth hospitalization in mothers with multiple sclerosis and their newborns. Neurology. 2013;80:447-452
[IF=8.3 (2012)]

Contribution of my group: 95%.

57. Kowalec K, Carleton B, Tremlett, H. The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis (review article). Multiple Sclerosis and Related Disorders. 11 January 2013 [online]

Contribution of my group: 75%.

58. Marrie RA, Fisk JD, Yu BN, Leung S, Elliott L, Caetano P, Warren S, Evans C, Wolfson C, Svenson LW, Tremlett H, Blanchard JF, Patten SB; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol. 2013 Feb 6;13:16. doi: 10.1186/1471-2377-13-1

Contribution of my group: 5%.

59. Lu E, Zhu F, van der Kop M, Dahlgren L, Synnes A, Sadovnick A, Traboulsee A, Tremlett, H; the British Columbia Multiple Sclerosis Clinic Neurologists.Labor induction and augmentation in women with multiple sclerosis. Mult Scler J. 2013 Feb 5. [Epub ahead of print]

Contribution of my group: 95%.

60 Lu E, Wei B, Guimond C, Synnes A, Sadovnick AD, Dahlgren L, Traboulsee A, Tremlett, H. Safety of disease-modifying drugs for multiple sclerosis in Pregnancy: Current challenges and future considerations for pharmacovigilance. Expert Rev Neurother. 2013 Mar;13(3):251-60; quiz 261

Contribution of my group: 95%.

61. Lange AP, Zhu F, Sayao AL, Sadjadi R, Alkabie S, Traboulsee AL, Costello F, Tremlett, H.
Retinal nerve fiber layer thickness in benign multiple sclerosis. Mult Scler. 2013 Feb 11. [Epub ahead of print]

Contribution of my group: 50%.

62. Menon S, Shirani A, Zhao Y, Oger J, Traboulsee AL, Freedman MS, UBC Hospital MS Clinic neurologists and Tremlett, H. Characterising aggressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2013. Published online 6 June 2013, 10.1136/jnnp-2013-304951

Contribution of my group: 95%.

Selected[H1] for by the journal as the ‘Editor’s choice article’ and published with a special podcast: https://soundcloud.com/bmjpodcasts/aggressive-ms-and

63. Lu E, Zhao Y, Dahlgren L, Preston R, van der Kop M, Synnes A, Sadovnick AD, Traboulsee A, Tremlett, H; On behalf of the British Columbia Multiple Sclerosis Clinic Neurologists. Obstetrical epidural and spinal anesthesia in multiple sclerosis. J Neurol. 2013 Jul 18. [Epub ahead of print]

64. Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H. J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1096-102. doi: 10.1136/jnnp-2013-307238. Epub 2014 Mar 4.

65. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130-1135.

66. Charles JA, Tremlett H, Lu E, Guimond C, Sadovnick AD. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2013 Mar 12;80(11):1068-1069.

67. Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. Interferon beta and long-term disability in multiple sclerosis. JAMA Neurol. 2013 May;70(5):651-2.

68. Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, Duddy M, Dobson C. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open. 2014;4(1):e004073corr1.

69. Lu E, Zhu F, Zhao Y, van der Kop M, Sadovnick A, Synnes A, Dahlgren L, Traboulsee A, Tremlett H. Birth outcomes of pregnancies fathered by men with multiple sclerosis. Mult Scler. 2014 Feb 5;20(9):1260-1264. [Epub ahead of print]

70. Lu E, Wang BW, Alwan S, Synnes A, Dahlgren L, Sadovnick AD, Tremlett H. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. CNS Drugs. 2014 Feb;28(2):89-94.

71. Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H. Assessment of cancer risk with β-interferon treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(10):1096-1102.

72. Lu E, Zhu F, Zhao Y, van der Kop M, Synnes A, Dahlgren L, Sadovnick AD, Traboulsee A, Tremlett H. Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs. CNS Drugs. 2014;28(5):475-482.

73. Razaz N, Nourian R, Marrie RA, Boyce WT, Tremlett H. Children and adolescents adjustment to parental multiple sclerosis: a systematic review. BMC Neurol. 2014;14:107.

74. Shirani A, Zhao Y, Karim ME, Petkau J, Gustafson P, Evans C, Kingwell E, van der Kop ML, Oger J, Tremlett H. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study. European Journal of Neurology. 2014;21(6):835-844.

75. Marrie RA, Fisk JD, Stadnyk KJ, Tremlett H, Wolfson C, Warren S, Bhan V, Yu BN; CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. Chronic Dis Inj Can. 2014 Jul;34(2-3):145-153.

76. Karim ME, Gustafson P, Petkau J, Zhao Y, Shirani A, Kingwell E, Evans C, van der Kop M, Oger J, Tremlett H. Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort. Am J Epidemiol. 2014;180(2):160.

77. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014;83(11):1022-1024.

78. Razaz N, Hertzman C, Marrie RA, Tremlett H, Boyce WT. Children of chronically ill parents: the silence of research. Child Care Health Dev. 2014 Sep;40(5):753-754.

79. Kowalec K, Kingwell E, Yoshida EM, Marrie RA, Kremenchutzky M, Campbell TL, Wadelius M, Carleton B, Tremlett H. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opinion on Drug Safety. 2014;13(10):1305-1317.

80. Evans C, Zhu F, Kingwell E, Shirani A, van der Kop ML, Petkau J, Gustafson P, Zhao Y, Oger J, Tremlett H. Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiol Drug Saf. 2014;23(11):1213-1222.

81. Bove R, Alwan S, Friedman JM, Hellwig K, Houtchens M, Koren G, Lu E, McElrath TF, Smyth P, Tremlett H, Sadovnick AD. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol. 2014;124(6):1157-1168.

82. Bueno AM, Sayao AL, Yousefi M, Devonshire V, Traboulsee A, Tremlett H. Health-related quality of life in patients with longstanding ‘benign multiple sclerosis’. Mult Scler Relat Disord. 2015;4(1):31-38.

83. Razaz N, Tremlett H, Boyce WT, Guhn M, Joseph K, Marrie RA. Impact of parental multiple sclerosis on early childhood development: A retrospective cohort study. Mult Scler. 2015 Jan 12. [Epub ahead of print]

84. McKay KA, Kwan V, Duggan T, Tremlett H. Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review. Biomed Res Int. 2015;2015:1-11.

85. McKay KA, Tremlett H. The systematic search for risk factors in multiple sclerosis. Lancet Neurol. 2015;14(3):237-238.

86. Tremlett H, Dai DL, Hollander Z, Kapanen A, Aziz T, Wilson-McManus JE, Tebbutt SJ, Borchers CH, Oger J, Cohen Freue GV. Serum proteomics in multiple sclerosis disease progression. Journal of Proteomics. 2015;118:2-11.

87. Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, Tilling K, Ben-Shlomo Y, Dobson C. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol. 2015;14(5):497-505.

88. Zhang T, Shirani A, Zhao Y, Karim ME, Gustafson P, Petkau J, Evans C, Kingwell E, van der Kop M, Zhu F, Oger J, Tremlett H and the BC MS Clinic Neurologists. Beta‐interferon exposure and onset of secondary progressive multiple sclerosis. European Journal of Neurology. 2015;22(6):990-1000.

In Press

Invited Editorials

1. Banwell, B and Tremlett H Coming of Age: The Use of Immunomodulatory Therapy in Paediatric Multiple Sclerosis. Neurology 2005; 64:778-779.

Contribution: Independently reviewed article referred to in the Editorial. Co-wrote the invited editorial. 50% effort.

2. Kingwell, E and Tremlett H. Interferons and Multiple Sclerosis: Is it plausible that beta-interferon treatment could influence the risk of cancer among MS patients? Expert Review of Neurotherapeutics 2009;  9:1263-1265

Contribution: Co-wrote the invited editorial. 50% effort.

3. Franklin, G and Tremlett H. Multiple sclerosis and pregnancy: What should we be telling our patients? Neurology 2009; 73(22):1820-2

Contribution: Co-wrote the invited editorial. 50% effort.

4. Tremlett H. Epidemiology in multiple sclerosis has had its day: there are no more unanswered questions – No.Mult Scler. 2012 Feb;18(2):138-9

5. Tremlett H and Lucas R. The risks for falls and fractures in multiple sclerosis. Neurology (accepted Feb/2012)

 

Book Chapters

1.  Marrie RA, Tremlett H Chapter 5: Epidemiology of multiple sclerosis. In: The Future of MS Treatment. Editors: Cohen J and Rudick R. 2011. Cambridge University Press

Research Letters and case reports

1. Tremlett H: Oral versus intravenous corticosteroids in acute relapses of Multiple Sclerosis. Lancet 1997;340:1696-1697.

2. Tremlett H, Luscombe DK: Unsubstantiated treatment (letter). Pharmaceutical Journal 1998;260:308.

3. Tremlett H, Luscombe DK: Use of desmopressin (letter). Pharmaceutical Journal 1998;260:201.

4. Tremlett H, J Evans, C Rogers, CM Wiles, DK Luscombe General practitioners’ prescribing data for multiple sclerosis patients indicates a link with asthma; British Journal of General Practice; 2000; 50(453);323.

5. Tremlett H. Effects of seasons on MRI-measured disease activity in patients with MS); Ann Neurol; 2001;50(3);422.

6. Tremlett H, Griggs RC. Liver and thyroid function and autoimmunity during interferon-ß1b treatment for MS Neurology; 2002;58:1868. 

7. Tremlett H, Yoshida E, Oger J. Liver injury associated with the IFNBs for MS: a comparison between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im) Neurology 2004;63:1142-1143 (http://www.neurology.org/cgi/content/full/63/6/1142?etoc)

8. Tremlett H, Traboulsee T. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology; 2005;64(1):174. 

9. Tremlett H: What went wrong in the natalizumab trials Comment? Lancet 2006; 367:1484-1485

10. Tremlett H, Sayao AL, Devonshire V. Longitudinal follow-up of ‘benign’ multiple sclerosis at 20 years. Neurology 2007;69(9):938

11. Koch M, Mostert J, De Keyser J, Tremlett H, Filippini G. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis. Ann Neurol. 2007; 63(1):125-126

Contribution: Drafting and editing letter. 20% effort

12. Gibbs  ETremlett  H,  Ball  N,  Hashimoto S  Malignant melanoma in a multiple sclerosis patient with persistent neutralizing antibodies to interferon beta. European Journal of Neurology 2008, 15(1): e4

Contribution: Drafting and editing letter. 10% effort

13. Hashimoto S, Ball  N, Tremlett  H   Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report. Multiple Sclerosis. 2009;15:521-522

Contribution: Drafting and editing case report. 30% effort

14. Tremlett  HFu P, Yoshida E,  Hashimoto S  Symptomatic liver injury (hepatotoxicity) associated with administration of complementary and alternative products (Ayurveda-AP-Mag Capsules®) in a beta-interferon treated multiple sclerosis patient. European Journal of Neurology 2011 Jul;18(7):e78-9

Contribution of my group: 80%.

15. Kowalec K, Yoshida EM, Traboulsee A, Carleton BC, Tremlett H. Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. Multiple Sclerosis and Related Disorders 2012 2(1): 57-59.

a place of mind, The University of British Columbia

Pharmacoepidemiology in MS (PiMS)
2211 Wesbrook Mall,
Vancouver, BC, V6T 2B5, Canada
Email:

Emergency Procedures | Accessibility | Contact UBC  | © Copyright The University of British Columbia